Indeed, we show that aldometanib effectively promotes glucose absorption by promoting the activation of muscular AMPK and inhibits lipogenesis by hepatic AMPK, thereby improving glucose homeostasis and alleviating fatty liver and NASH. The gene discussed is PRKAA1; the disease is metabolic dysfunction-associated steatohepatitis.